David Baxley Spetzler - 03 Mar 2025 Form 4 Insider Report for Caris Life Sciences, Inc.

Role
President
Signature
/s/ J. Russel Denton, Attorney-in-Fact
Issuer symbol
CAI on Nasdaq
Transactions as of
03 Mar 2025
Net transactions value
-$13,794,277
Form type
4
Filing time
23 Jun 2025, 18:41:24 UTC
Next filing
17 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Spetzler David Baxley President C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING /s/ J. Russel Denton, Attorney-in-Fact 23 Jun 2025 0002071953

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAI Common Stock Disposed to Issuer $13,029,467 -700,509 -67% $18.60 351,240 03 Mar 2025 Direct F1, F2
transaction CAI Common Stock Award $0 +132,428 +38% $0.000000 483,668 18 Jun 2025 Direct F3
transaction CAI Common Stock Options Exercise $183,000 +75,000 +16% $2.44 558,668 20 Jun 2025 Direct
transaction CAI Common Stock Tax liability $947,810 -34,782 -6.2% $27.25 523,886 20 Jun 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAI Stock Option Award $0 +750,000 $0.000000 750,000 03 Mar 2025 Common Stock 750,000 $18.60 Direct F4
transaction CAI Stock Option Options Exercise $0 -75,000 -100% $0.000000 0 20 Jun 2025 Common Stock 75,000 $2.44 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note.
F2 Includes 151,750 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreements, which securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.
F3 Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
F4 The stock option vested 60% at grant and will vest 20% on August 11, 2025 and 20% on August 11, 2026. These securities were previously reported on the Reporting Person's Form 3.
F5 The stock option is fully vested and exercisable.